NCT06764160View on ClinicalTrials.gov

Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 6, 2025

Primary Completion Date

December 19, 2025

Study Completion Date

December 19, 2025

Conditions
Generalized Myasthenia Gravis (gMG)Refractory gMG
Interventions
DRUG

Eculizumab

Participants will receive Eculizumab via intravenous (IV) infusion.

Trial Locations (10)

130021

Research Site, Changchun

200040

Research Site, Shanghai

215006

Research Site, Suzhou

266035

Research Site, Qingdao

350001

Research Site, Fuzhou

410008

Research Site, Changsha

430030

Research Site, Wuhan

510080

Research Site, Guangzhou

510620

Research Site, Guangzhou

518053

Research Site, Shenzhen

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY